From roughly $85,000 per kilogram in 1981, the price of putting cargo into orbit fell to about $1,500 per kilogram by 2024, according to a New Zealand government sector study. Getting things up has stopped being the hard part of the space business. Getting them back down, intact and on a schedule, is now the bottleneck, and a small group of companies is building the return trip as a product.
The commercial case no longer rests on the International Space Station (ISS): Varda has signed a paying pharmaceutical company, Merck has reformulated a drug using microgravity crystals, and Space Forge has run the first free-flying semiconductor furnace in orbit.
The economics only work for cargo worth more per kilogram than launch and reentry cost. That narrows the near-term market to drugs, and that is where the first real revenue is appearing.
The ISS gave researchers thirty years of free access to weightlessness. It retires around 2030. The companies now raising money are betting that the customers who used that subsidy will start paying for the same experiments on commercial platforms.
TIMELINE: Commercial microgravity manufacturing
─────────────────────────────────────────────────────────────
1981 ──── 2000s ──── 2020s ──── 2026 ◉ NOW ──── 2028 🔥 NEXT
$85k/kg ISS era W-series Outlier Outlier
to orbit research landings NZ$10.5M first
+ Keytruda pre-seed test flight
1981: launch economics still exclude manufacturing
2000s: ISS proves crystals, under a government subsidy
2024: Varda lands capsules; Merck reformulates Keytruda
2026: United Therapeutics pays Varda; Outlier raises
2028: Outlier targets first capsule test flight
Anchors: Outlier Space press release (July 2026), MIT Technology Review, SpaceNews
Why gravity ruins a crystal
Manufacturing in orbit is not about weightlessness as a novelty. It is about what gravity does during crystallization on Earth. In a terrestrial flask, denser molecules sink, lighter ones float, and convection currents stir the mix while a crystal is still forming. Each of those motions can seed a defect in the lattice.
Remove gravity and the forces mostly disappear. "You don't have sedimentation forces, you don't have flotation forces, and critically you don't have convection currents," Sarah Kessans, a University of Canterbury professor working on microgravity crystallization, told RNZ in September 2025.
The result is crystals that are larger, more uniform, and sometimes structured in ways Earth cannot produce at all. The commercial trick is finding molecules where that difference is worth real money. A kilogram of a weight-loss drug can exceed US$100 million at retail, per MIT Technology Review, against a launch bill of a few thousand dollars. At that ratio the physics stops being a science project.
Value density drives what flies
Per-kilogram value decides what earns a round trip at current launch prices. Crystals that improve an existing drug clear the bar; bulk materials mostly do not. · MIT Technology Review, 2026
The subsidy that is ending
For three decades the ISS was the only microgravity laboratory, and it ran on government money. Pharma companies could test crystallization theory there without building a return vehicle or paying launch costs. That arrangement produced the science and almost none of the industrial follow-through, because a demonstration on a subsidized station is not a supply chain.
The station is scheduled to be decommissioned near the end of the decade. Its commercial successors, from Axiom to Vast, are years from full operation. In the gap, the only reliable way to run a microgravity process and get the product back is a purpose-built capsule. That is the opening Outlier Space, Varda and Space Forge are each attacking from different directions.
Varda sells the return trip
Varda Space Industries, based in El Segundo, California, treats reentry as the core engineering problem. Its W-series capsules manufacture pharmaceutical material in orbit and land it under parachute in the Australian outback, at the Koonibba Test Range run by Southern Launch. W-6 touched down there in May 2026 after validating autonomous navigation during hypersonic reentry and a thermal-protection tile developed by Sandia National Laboratories. W-5 had landed in January carrying the company's own vertically integrated satellite bus and heatshield.
The milestone that mattered commercially came in May 2026, when United Therapeutics, a Nasdaq-listed company with a market value around US$25 billion, agreed to fund processing of compounds for rare pulmonary disease across multiple missions. Delian Asparouhov, a Varda co-founder, calls it the first time a public company has contracted to manufacture a physical product in space. That distinction separates a research program from a purchasing decision.
Merck has already shown what the endpoint looks like. The company used microgravity crystallization work to reformulate its cancer drug Keytruda, moving it from a four-hour intravenous infusion toward a version that can be injected at home. Better crystal structure changed the delivery economics of a blockbuster.
The unit economics still hinge on a narrow claim: that a drug's crystal form affects its value enough to justify orbit. The company's chief strategy officer, Michael Reilly, frames the pitch as the first commercial path to products made in space. So far, the paying customers have been pharmaceutical companies.
Semiconductors are the harder prize
Space Forge, a Welsh company, is chasing a bigger market with a slower fuse. Its ForgeStar-1 satellite, launched in June 2025 under Europe's first in-space manufacturing licence, ran a furnace that produced plasma above 1,000 degrees Celsius in orbit in December 2025, the first free-flying commercial semiconductor growth tool ever operated in space. The successor, ForgeStar-2, will add a heat shield designed to return manufactured semiconductor material intact.
Single-crystal semiconductor growth in microgravity could produce substrates with fewer defects than terrestrial furnaces. If it works at volume, the prize is enormous. The risk is equally large: semiconductor material is far cheaper per kilogram than an improved drug, so the round-trip cost has to fall further before the math closes. Space Forge's bet is that it will, and that being first down the learning curve matters more than the current cost curve.
Outlier Space bets on being the landlord
Outlier Space, founded by Jamie France after nearly a decade at Rocket Lab, is taking neither the pharma-first nor the semiconductor-first path. It is building a reusable capsule it describes as an anti-gravity chamber, flying customer payloads on whichever rocket is available, and returning them to Earth. The company handles launch, orbit and reentry; the customer brings the experiment. One analyst description frames it as a landlord for a very specialized factory.
The NZ$10.5 million (about US$7.35 million) pre-seed closed in early September 2026, led by Auckland venture firm GD1 with Airtree, Side Stage Ventures and Investible participating. France spent his Rocket Lab years watching a fast follower to a larger incumbent compound into a multi-billion-dollar launch business, and he says reentry is where he wants to run the same play. The first test flight is targeted for 2028.
The model spreads the fixed cost of a return vehicle across pharmaceutical, biotech, materials and semiconductor customers, none of whom wants to own reentry engineering. That is the same logic that made dedicated launch brokers viable: capabilities that are essential to an industry but peripheral to any single product line tend to get built by a specialist.
Reentry has to become repeatable, not heroic. Each successful landing lowers the insurance premium the next customer pays.
The ISS gap has to hold long enough for commercial platforms to capture the habit of running experiments, before station successors return.
At least one paying customer needs to move from a demonstration to a standing order, the step United Therapeutics has already taken.
As we wrote in August, in-orbit biomanufacturing milestones such as Auxilium's printed-tissue experiment on the ISS have been reshaping what gets produced above the atmosphere. What has changed since is the shape of the demand: the customers are no longer agencies running demonstrations but companies signing contracts.
What changes the answer
None of these companies has yet proven a repeatable, paying manufacturing pipeline. Varda is closest, with two landings in 2026 and a paying pharma partner. Outlier Space is a pre-seed company whose first flight is two years away. Space Forge has demonstrated the furnace but not the return of a product.
The honest reading of the sector in September 2026 is that it has cleared the proof-of-concept stage and entered the capital-intensive stage, where the winners will be decided by who can land capsules on schedule and on cost, mission after mission. Launch cadence is the constraint that used to bind; reentry cadence is the one binding now.
For an investor the distinction matters. A research subsidy funds capability. A commercial contract funds a supply chain. The first real contracts in microgravity manufacturing appeared in 2026, and they were signed by pharmaceutical companies, the only buyers so far whose products justify the round trip.
That may be the narrowest version of the market. It is also the only version with revenue attached.